A self-injectable device with a pre-charged drug dosage is an autoinjector. It offers various benefits, including dose precision, higher patient compliance, less needlestick injuries, and increased efficiency of healthcare personnel. Drugs are delivered via subcutaneous or intramuscular injection. Numerous emergency illnesses, including migraine, allergy, status epilepticus, diabetes, psoriasis, multiple sclerosis, and rheumatoid arthritis, require the usage of these devices. Autoinjectors are widely used in hospitals, clinics, and home care facilities all over the world because of their characteristics.
The market for autoinjectors in 2021 was USD 2.88 billion and will reach USD 12.67 billion by 2030, growing at a 17.9% CAGR During 2021-2030.
Anaphylactic shock is becoming more common, auto-injector awareness is growing, and patients prefer self-injection as the growth driver for the worldwide auto-injectors market.
Additionally, the industry is expanding due to the growing use of anaphylaxis, food allergies, the EpiPenautoinjector, autoinjector pens, and autoinjector syringes. Additionally, medical professionals mainly employ autoinjectors due to their advantages, which include precise medicine doses, reducing needle fears, etc.
The market for autoinjectors is expanding primarily as a result of factors such as the rising prevalence of targeted therapies, the rising incidence of anaphylaxis, the rising consumer preference for drug self-administration, the benefits of usability, the rising number of regulatory body approvals, the simple availability of generic autoinjectors, government support, favorable reimbursements, technological advancement, and others
Additionally, a 2019 study from the European Journal of Allergy and Clinical Immunology found that the world’s Anaphylaxis in children occurs at a rate of 1 to 761 per 100,000 person-years overall, compared to 1 to 77 per 100,000 for anaphylaxis brought on by food. The rising rate of Anaphylaxis is fueling market expansion.
The availability of alternative medication delivery methods and the higher cost of autoinjectors constrain the global autoinjector market. Another obstacle to the size of the autoinjector business is the difficulty in obtaining autoinjectors.
Future potential in this market sector may be attributed to advancements in technology and pharmaceutical businesses, as well as a rise in R&D spending, fueling the expansion of the autoinjector market.
By Therapy, the autoinjector market is segmented into rheumatoid arthritis, anaphylaxis, diabetes, multiple sclerosis, and others. Rheumatoid arthritis led the overall market in 2021. This was largely due to its frequent occurrence across the globe. The CDC estimates that each year in the United States, 43.7 million people (22.7 percent of the total population) are affected by arthritis, gout, lupus, rheumatoid arthritis, and fibromyalgia.
The autoinjectors market is divided into disposable and reusable autoinjectors by type. The market for autoinjectors has the biggest share of disposable autoinjectors in 2021. This makes it the most popular autoinjector among patients with poor dexterity or visual impairments due to its simplicity of use and the presence of a built-in glass syringe (which eliminates the need to manually load a glass syringe).
Route of administration insights
By route of administration, the market is segmented into subcutaneous and intramuscular. The subcutaneous segment had the most market share and is predicted to expand the fastest throughout the forecast. This is mostly due to the regulatory authorities’ increasing acceptance of products for the treatment of chronic diseases.
By end-user, the autoinjectors market is segmented into hospitals and clinics, ambulatory care settings, and home care settings. Due to the rapid aging of the world’s population and the rising desire for inexpensive drug administration, the home care settings category held the biggest market share in 2021.
North America was the biggest market for autoinjectors, followed by Europe and the Asia-Pacific region. The North American regional market is growing due to elements including the rising frequency of anaphylaxis and the availability of favorable reimbursements. In addition, the developed economies of the United States and Canada, where autoinjector use is common, and consumer awareness is high, are advantageous for market expansion. Other microeconomic factors that support market expansion include rising healthcare costs, a high rate of affordability, and a more favorable regulatory climate.
During the forecast year, Asia-Pacific will have the fastest growth rate. Numerous important autoinjector device manufacturers are drawn to the Asia Pacific region due to the region’s sizable diabetic population and rising healthcare costs.
- Dickinson and Company
- GlaxoSmithKline plc
- Antares Pharma
- Merck KGaA
- Johnson & Johnson
- Eli Lilly and Company
- Teva Pharmaceutical
The market for autoinjectors in 2021 was USD 2.88 billion and will reach USD 12.67 billion by 2030, growing at a 17.9% CAGR During 2021-2030. Due to an increase in anaphylaxis instances, the autoinjector market will significantly grow in the next years. Additionally, companies will enhance their R&D efforts to create simple, affordable, and new technology-based autoinjectors for the treatment of chronic illnesses such as rheumatoid arthritis and multiple sclerosis throughout the projection period.